Navigation Links
Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development

To ignite a life-threatening infection in the body, a virus such as HIV invades body cells by first merging, or fusing, with the cell's outer membrane. Once inside the cell, the invading microbe's genetic material takes over, turning the 'host' cell into a factory to produce more copies of the virus, which then spill out to invade other cells in the body.

Scientists had assumed that once a virus begins fusing with a cell's membrane, infection of the host cell was inevitable. Thus, antiviral drug development has largely focused on preventing events that happen either before or after this step.

However, a multi-institutional team of researchers is reporting that it has detected an intermediate stage between the virus' merger with the cell membrane and the microbe's delivery of its genetic contents into the cell, when the fate of the host cell still hangs in the balance.

This intermediate stage, which can last several minutes, may represent a window of opportunity for drug development. The remarkable findings, captured on video, were published by the Proceedings of the National Academy of Sciences online on June 3. Biophysicist Gregory Melikyan of Rush University Medical Center in Chicago and microbiologist John Young of the Salk Institute for Biological Studies filmed individual viruses fusing with a host cell membrane. Avian sarcoma and leukosis virus (ASLV), a virus that is in the same class as HIV, was used in the study.

The researchers discovered that once the virus fuses with the host cell membrane the hole, or pore, through which the virus unloads its deadly genetic cargo into the host cell does not open up right away; instead, a small pore can persist for several minutes before adopting its final size, or (in rare cases) closing permanently.

This 'intermediate stage,' as the scientists describe this time interval, was not known to exist for virus-cell fusion events. The net effect is that the invading virus is held up for a significant amount of time and, in the rare cases in which the pore does not open, it fails to infect the cell at all.

"It's like a space craft docking on a space station," said Young. "If you try to open the inner door before the pressures have equalized, you can tease it open a little bit but it keeps closing on you until there's enough pressure in the airlock to allow it to open all the way."

Melikyan explained, "The pore is an unstable structure at that moment: some pores will open and some won't. It's a crucial point in viral entry because it's critical for the pore to enlarge sufficiently for the genetic material to pass into the host cell."

The researchers are excited by this study because even a brief pause during the process by which a virus invades a cell provides a possible new drug target in the fight against HIV and other similar microbes.

"Our experimental system does pause frequently for hundreds of seconds," said Melikyan. "How this happens in real life is hard to say.

"But our model," he added, "is likely to apply to any virus such as HIV that fuses with the cell membrane and shares the same fusion proteins, so it certainly provides a new target. Also, existing drugs can be re-evaluated to pinpoint at what stage they actually work, to fine-tune their activity."

The experimental set-up for this study was devised by Young and Melikyan last year to investigate viral infection in a manner as close to 'real life' as possible. The researchers filmed the microscopic viruses, which are only 100 nanometers across, by labeling them with fluorescent dyes and recording at one frame every 7 seconds. (For comparison purposes, a human hair is 80,000 nanometers thick.) ASLV is a useful model for several viruses, including Ebola, the 'flu, and measles, as well as HIV.

"This system is especially well suited for these types of studies because the fusion mechanism of this virus can be finely manipulated and moni tored in the lab, allowing for an exquisite level of control of the whole process," said Young. "This allows us to do things that are not possible with other systems."

The next stage is for researchers to confirm that other viruses such as HIV also have an intermediate step. Preliminary data from the Melikyan laboratory indicate that this may be the case for HIV. "We already know that the entire HIV fusion sequence is very slow, sometimes taking several hours," said Melikyan. "It is not inconceivable that it, too, has an intermediate step that lasts several minutes, giving us an adequate time window for drug action."


'"/>

Source:Salk Institute


Related biology news :

1. Genomic sequences processed in minutes, rather than weeks
2. Scientists unpick genetics of first 15 minutes of life
3. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
4. NYU biologists map out early stages of embryo formation
5. Wright bros. upstaged! Dinos invented biplanes
6. Driver of anthrax toxicity could lead to late-stage therapy
7. Front-line immune cells mature in four stages, study shows
8. New research finds surveys of larval-stage organisms effective for measuring marine biodiversity
9. Major cancer study aims to identify protein markers for early-stage disease
10. Nano-devices hold promise for early-stage cancer detection
11. Novel vaccine shows promise against early-stage breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology: